Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACIF: Polypill Approach for Multiple Cardiovascular Risk Factors
NCT07679828Recruiting
- Sponsor
- China Medical University
- Start
- Jul 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Randomised, open-label trial of olmesartan, amlodipine, rosuvastatin, ezetimibe, dapagliflozin and 1 more in hypertension (HTN), dyslipidemia and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by China Medical University. Primary endpoints: 10-year cardiovascular disease risk estimated by the PREVENT equations at 12 months and Composite cardiovascular disease outcome at 36 months. Started Jul 2026; status: recruiting.
02
Drugs
olmesartanamlodipinerosuvastatinezetimibedapagliflozin
03
Conditions
hypertension (HTN)dyslipidemiatype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07679828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07679828.